Loading...

Home
ETF
BFRIW

BFRIW

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

BFRIW News

BIOFRONTERA INC - FDA Establishes PDUFA Deadline for September 28, 2026

BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA

BIOFRONTERA INC PLANS TO FILE SNDA WITH FDA IN Q3 2026

Feb 09 2026moomoo

BIOFRONTERA INC Reports 73.1% Lesion Clearance in FAS and 80.3% in PPS

Feb 09 2026moomoo

BIOFRONTERA INC - AMELUZ PDT SHOWS 45.6% CLEARANCE RATE IN PHASE 3 TRIAL

Feb 09 2026moomoo

BIOFRONTERA INC - PRIMARY ENDPOINT MET WITH FULL CLEARANCE RATE OF AK LESIONS

Feb 09 2026moomoo

BIOFRONTERA REPORTS SUCCESSFUL PHASE 3 STUDY RESULTS FOR AMELUZ® PDT TREATMENT OF ACTINIC KERATOSES ON EXTREMITIES, NECK, AND TRUNK, ACHIEVING PRIMARY ENDPOINT

Feb 09 2026moomoo

Biofrontera Inc. Announces Financial Results for Q3 2025 and Offers Business Update

Nov 13 2025Newsfilter

Biofrontera Inc. Completes Acquisition of All US Assets for Ameluz® and RhodoLED® from Biofrontera AG

Oct 23 2025Newsfilter

Biofrontera Inc. Set to Attend Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 26 2025Newsfilter

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13 2025Newsfilter

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Aug 11 2025Newsfilter

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Jun 11 2025Newsfilter

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Jun 03 2025Newsfilter

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

May 15 2025Newsfilter

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

May 15 2025Yahoo Finance